Bo Martin Bibby

Angiotensin II receptor blockade does not protect against progressive loss of residual renal function in hemodialysis patients: A randomized controlled trial (SAFIR study)

Research output: Contribution to conferenceConference abstract for conferenceResearch

  • Krista Dybtved Kjærgaard
  • Christian Daugaard Peters
  • Bente Jespersen
  • Ida N Tietze, Medicinsk Afdeling, Regionshospitalet Viborg, Denmark
  • Jens Kristian Madsen, Denmark
  • Birgitte Bang Pedersen, Denmark
  • Marija K Novosel, Department of Medicine, Fredericia Hospital, Fredericia, Denmark., Denmark
  • Kathrine Skaaning Laursen, Nyremedicinsk Afdeling, Aalborg Sygehus, Institut for klinisk medicin - Nyremedicinsk Afdeling, Medicinsk Center, Aalborg Sygehus, Denmark
  • Bo Martin Bibby
  • Charlotte Strandhave, Denmark
  • Jens Dam Jensen
Background: Glomerular filtration rate (GFR) declines during chronic dialysis treatment. In peritoneal dialysis, blockade of the renin-angiotensin-aldosterone system reduces GFR decline. Observational studies suggest that similar treatment may preserve renal function in hemodialysis (HD).
Methods: The SAFIR study is a multicenter randomized placebo-controlled double-blinded trial initiated by the investigators with one-year follow-up. Inclusion criteria were adult HD patient with urine output > 300 mL/24h, HD vintage < 1 year, and cardiac ejection fraction > 30%. Patients were included from six HD centers and randomized to placebo or the angiotensin II receptor blocker irbesartan 300 mg daily. Target systolic blood pressure (BP) was 140 mmHg. Outcomes were GFR measured as the mean of creatinine and urea renal clearance, urine volume and time to anuria.
Results: Of the 82 patients randomized (placebo n=41/irbesartan n=41), 56 completed one year of treatment. The groups were comparable at baseline (means): males 26/30, age 62/61 years, HD vintage 137/148 days (medians), HD time 10/11 hours/week, urine volume 1.19/1.26 L/24h (medians), GFR 4.8/5.7 mL/min/1.73m2. The target BP level was reached in both groups and BP did not differ significantly between groups over time. Adverse event rates were similar. GFR declined by 1.7 (1.2 to 2.3) (mean (95% CI)) mL/min/1.73m2/year in the placebo group and by 1.8 (1.1 to 2.4) mL/min/1.73m2/year in the irbesartan-treated group. Mean difference (baseline-12 months) between groups was -0.0 (-0.8 to 0.8). In each group, four patients became anuric.
Conclusions: At equal BP levels, we found that irbesartan treatment did not affect the decline in GFR or urine volume significantly during one-year treatment in HD patients. Irbesartan treatment was safely used in the studied population.
Original languageEnglish
Publication year3 May 2014
Publication statusPublished - 3 May 2014
EventAnnual meeting of the Danish Society of Nephrology: Årsmøde i dansk nefrologisk selskab - Hotel Scandic, Aarhus City, Aarhus, Denmark
Duration: 2 May 20143 May 2014


ConferenceAnnual meeting of the Danish Society of Nephrology
LocationHotel Scandic, Aarhus City

See relations at Aarhus University Citationformats

ID: 75292219